Dr. Nihal E. Abdulla, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 391
Licensed in Texas since 2008, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A120904 (first issued 2012; current) · CA license 120904 -
Medical Oncology Physician
TX license M9110 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Memorialcare Long Beach Medical Center Long Beach, CA
- Memorialcare Orange Coast Medical Center Fountain Valley, CA
- St Mary Medical Center Long Beach, CA
- Uci Health-Lakewood Lakewood, CA
Medical groups
- Cancer and Blood Specialty Clinic (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 391
- Services billed
- 57,047
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 27,750 | 13 |
| Injection, denosumab, 1 mg | 3,960 | 24 |
| Injection, dexamethasone sodium phosphate, 1 mg | 810 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 343 | 141 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 252 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 232 | 107 |
| Injection of drug or substance under skin or into muscle | 189 | 36 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 143 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 127 | 69 |
| Administration of chemotherapy into vein, 1 hour or less | 119 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamoxifen Citrate Other prescribers in Los Alamitos, CA | 131 |
| Prednisone Other prescribers in Los Alamitos, CA | 116 |
| Anastrozole Other prescribers in Los Alamitos, CA | 110 |
| Abiraterone Acetate | 81 |
| Letrozole Other prescribers in Los Alamitos, CA | 80 |
| Ondansetron Odt (ondansetron) Other prescribers in Los Alamitos, CA | 75 |
| Eliquis (apixaban) Other prescribers in Los Alamitos, CA | 72 |
| Dexamethasone Other prescribers in Los Alamitos, CA | 69 |
| Procrit (epoetin alfa) | 59 |
| Hydroxyurea Other prescribers in Los Alamitos, CA | 52 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 61 companies reported 262 payments worth $9,150 in total to this clinician.
| Janssen Biotech, Inc. | $2,415 |
|---|---|
| Janssen Scientific Affairs, LLC | $1,080 |
| AstraZeneca Pharmaceuticals LP | $590 |
| Celgene Corporation | $420 |
| Pfizer Inc. | $398 |
| E.r. Squibb & Sons, L.l.c. | $342 |
| Cardinal Health 110 LLC | $275 |
| Novartis Pharmaceuticals Corporation | $260 |
| Food and Beverage | $5,654 |
|---|---|
| Consulting Fee | $3,335 |
| Education | $101 |
| Travel and Lodging | $60.59 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jul 17, 2025 | Consulting Fee TECVAYLI · Oncology | $1,980 |
| Janssen Scientific Affairs, LLC Nov 18, 2025 | Consulting Fee RYBREVANT · Oncology | $1,080 |
| Cardinal Health 110 LLC Jan 9, 2025 | Consulting Fee | $275 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
| Janssen Biotech, Inc. Jul 17, 2025 | Travel and Lodging TECVAYLI · Oncology · travel to LOS ANGELES, CA | $35.84 |
| Amgen Inc. Jul 31, 2025 | Education in-kind | $32.72 |
| Janssen Biotech, Inc. Jun 25, 2025 | Travel and Lodging TECVAYLI · Oncology · travel to LOS ANGELES, CA · in-kind | $24.75 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 10 companies. The companies reported $2,514,625 in research payments for these studies, mostly to the institutions running them.
- An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus letrozole compared to CDK46 inhibitor plus letrozole in participants over 18 years of age with hormone receptor hrpositive HER2NEGATI…
Pfizer Inc. - A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05100862 - A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated…
Janssen Research & Development, LLC - An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastati…
Merck Sharp & Dohme LLC - PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC
Genentech, Inc. - A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Tr…
Merck Sharp & Dohme LLC - An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 …
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC - Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell …
Janssen Research & Development, LLC - A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors.
Genmab U.S., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.